Exploring the anti-glioma mechanism of the active components of Cortex Periplocae based on network pharmacology and iTRAQ proteomics in vitro
Advances in Clinical and Experimental Medicine · 2023
DOI: 10.17219/acem/161724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Jing Huan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine College, Guangzhou University of Chinese Medicine, China. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Glioma. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine College, Guangzhou University of Chinese Medicine, China.
- Department of Acupuncture and Moxibustion, Linyi People's Hospital, China.
- Central Laboratory, Linyi People's Hospital, China.
- Biobank, Linyi People's Hospital, China.
- Department of Neurology, Linyi People's Hospital, China.
Zitieren
APA
Huan, J., You, C. P., Lu, Y. C., & Che, F. Y. (2023). Exploring the anti-glioma mechanism of the active components of Cortex Periplocae based on network pharmacology and iTRAQ proteomics in vitro. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/161724
Vancouver
Huan J, You CP, Lu YC, Che FY. Exploring the anti-glioma mechanism of the active components of Cortex Periplocae based on network pharmacology and iTRAQ proteomics in vitro. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/161724
BibTeX
@article{Huan2023,
author = {Huan, Jing and You, Cui-Ping and Lu, Yu-Cheng and Che, Feng-Yuan},
title = {Exploring the anti-glioma mechanism of the active components of Cortex Periplocae based on network pharmacology and iTRAQ proteomics in vitro},
journal = {Advances in Clinical and Experimental Medicine},
year = {2023},
doi = {10.17219/acem/161724}
}
EUVIMED